

Novel DMARDs on the basis of a new concept of dual cytokine regulation, TNF- suppression and IL-10 augmentation

Tokushi Hanano^a, Kunitomo Adachi^b, Yoshiyuki Aoki^b, Hiroshi Morimoto^b, Yoichi Naka^b, Masao Hisadome^b, Tetsuko Fukuda^b and Hiroshi Sumichika^b

^a Drug Discovery Laboratories, Pharmaceutical Research Division, Yoshitomi Pharmaceutical Industries, Ltd., 7-25 Koyata 3-chome, Iruma-shi, Saitama 358-0026, Japan

^b Drug Development Laboratories, Pharmaceutical Research Division, Yoshitomi Pharmaceutical Industries, Ltd., 955 Koiwai, Yoshitomi-cho, Chikujo-gun, Fukuoka 871-8550, Japan

„...presumably due to ease of oxidative **metabolism** at their terminal phenyl ring. Fluoropyridine...than 4a (prevention of the oxidative **metabolism** of the pyridine ring of 4d by the fluorine...the PALLAS 1.2 package, a product of **CompuDrug** Chemistry Ltd (Budapest, Hungary). 6...”

Abstract

A series of arylpiperazine derivatives was synthesized to obtain agents showing apparent therapeutic effects in a chronic inflammatory animal model, starting from a lead possessing potent dual cytokine regulatory activity in vivo. We found a pyrimidylpiperazine derivative **17c** showing the dual regulatory activity and an excellent therapeutic effect in an adjuvant-induced arthritis model.

[Bioorganic & Medicinal Chemistry Letters](#)

[Volume 10, Issue 9](#), 1 May 2000, Pages 881-884